Prognosis of chronic myelomonocytic leukemia

Haematologica

Volumn 81, Issue 4, 1996, Pages 324-329

  Catalano, Lucio ^a   Improta, Salvatore ^a   De Laurentiis, Michelino ^a   Molica, Stefano ^b   Majolino, Ignazio ^c   Musto, Pellegrino ^d   Fragasso, Alberto ^e   De Placido, Sabino ^a   Rotoli, Bruno ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b PUGLIESE CIACCIO HOSPITAL   (Italy)

^c VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^e Presidio Ospedaliero   (Italy)

Author keywords

Chronic myelomonocytic leukemia; Myelodysplastic syndromes; Myeloproliferative syndromes

Indexed keywords

ADULT; AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; CHRONIC MYELOMONOCYTIC LEUKEMIA; DISEASE CLASSIFICATION; FEMALE; HEMATOPOIESIS; HUMAN; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASIA; MYELOPROLIFERATIVE DISORDER; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS;

EID: 0030326406     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Bennett JM, Catovsky D, Daniel MT, et al. for the FAB Cooperative Group. Proposal for the classification of the acute leukemias. Br J Haematol 1976; 33:451-8.
2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Sultan C. Proposal for the classification of myelodysplastic syndromes. Br J Haematol 1982; 51:189-99.
3. Ribera JM, Cervantes F, Rozman C. A multivariate analysis of prognostic factors in chronic myelomonocytic leukemia according to FAB criteria. Br J Haematol 1987; 65:307-11.
4. Akashi K, Shibuya T, Harada M, et al. Interleukin 4 suppresses the spontaneous growth of chronic myelomonocytic leukemia cells. J Clin Invest 1991; 88:223-30.
5. Catalano L, Majolino I, Musto P, et al. Alpha interferon in the treatment of CMML. Haematologica 1989; 74:577-81.
6. Greenberg PL, Dewald G, Sawyers C. Myeloproliferative disorders and myelodysplastic syndromes: recent therapeutic, cytogenetic, and molecular advances. American Society of Hematology Congress, Nashville, 1994. Educational Program Book, 21-33.
7. Worsley A, Oscier DG, Stevens J, Darlow S, Mufty GJ, Hamblin JJ. Prognostic features of chronic myelomonocytic leukemia: a modified Bournemouth score gives the best prediction of survival. Br J Haematol 1988; 68:17-21.
8. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
9. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34:187-220.
10. Fenaux P, Beuscart R, Lai JL, Jouet JP, Bauters F. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J Clin Oncol 1988; 6:1417-24.
11. Storniolo AM, Moloney WC, Rosenthal DS, Cox C, Bennett JM. Chronic myelomonocytic leukemia. Leukemia 1990; 4:766-70.
12. Michaux JL, Martiat P, for the Group Français de Cytogènètique Hèmatologique. Chronic myelomonocytic leukemia: single entity or heterogeneous disorder? A prospective multicenter study of 100 patients. Cancer Genet Cytogenet 1991; 55:57-65.
13. Aul C, Gattermann N, Heyll A, Germing V, Derigs G, Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposal for an improved scoring system. Leukemia 1992; 6:52-9.
14. Solal-Celigny P, Desaint B, Herrera A, et al. Chronic myelomonocytic leukemia according to FAB classification: analysis of 35 cases. Blood 1984; 63:634-8.
15. Kerkhofs H, Hermans J, Hook HL, Leeksma CHW. Utility of FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br J Haematol 1987; 65:73-81.
16. Alessandrino EP, Orlandi E, Brusamolino E, et al. Chronic myelomonocytic leukemia: clinical features, cytogenetics, and prognosis in 30 consecutive cases. Hematol Oncol 1985; 3:147-55.
17. Rotoli B, Formisano S, Martinelli V, Nigro M. Long-term survival in acute myelogenous leukemia complicated by chronic active hepatitis. N Engl J Med 1982; 307:1712-3.
18. Barton JC, Conrad ME. Beneficial effects of hepatitis in patients with acute myelogenous leukemia. Ann Intern Med 1979; 90:188.
19. del Canizo MC, Sanz G, San Miguel JF, et al. Chronic myelomonocytic leukemia clinicobiological characteristics: a multivariate analysis in a series of 70 cases. Eur J Haematol 1989; 42:466-73.
20. Molica S, Iannaccaro P, Alberti A. Chronic myelomonocytic leukemia: a test of a proposed staging system. Am J Hematol 1990; 35:129-30.
21. Musto P, Bodenizza C, Falcone A, et al. Prognostic relevance of serum thymidine kinase in primary myelodysplastic syndromes: relationship to development of acute myeloid leukaemia. Br J Haematol 1995; 90:125-30.
22. Michaux JL, Martial P. Chronic myelomonocytic leukemia (CMML). A myelodysplastic or myeloproliferative syndrome? Leuk Lymphoma 1993; 9:35-41.
23. Bennett JM, Catovsky D, Daniel MT, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposal by the French-American-British Cooperative Leukaemia Group. Br J Haematol 1994; 87:746-54.
24. +CML and chronic myelomonocytic leukemia. Blood 1991; 78:205-11.
25. Bassan R, Barbui T. Remission induction therapy for adults with acute myelogenous leukemia: towards the ICE age? Haematologica 1995; 80:82-90.